Jiangsu Nhwa Pharmaceutical Co., LTD (SHE:002262)

Market Cap	24.06B
Revenue (ttm)	6.02B
Net Income (ttm)	1.23B
Shares Out	1.02B
EPS (ttm)	1.21
PE Ratio	19.57
Forward PE	19.10
Dividend	0.36 (1.52%)
Ex-Dividend Date	May 14, 2025

Volume	7,178,757
Average Volume	8,891,841
Open	25.07
Previous Close	24.25
Day's Range	23.50 - 25.07
52-Week Range	20.36 - 29.30
Beta	-0.36
RSI	36.45
Earnings Date	Oct 25, 2025

About SHE:002262

Jiangsu Nhwa Pharmaceutical Co., LTD engages in production, marketing, and services related to central nervous system drugs in China. The company offers Duloxetine Hcl, Risperidone, Ziprasidone Hcl, Etomidate Fat Emulsion, Gabapentin, Zaleplon, etc., as well as Iptakalim, an anti-hypertension drug. It also provides penehyquinac acid hydrochloride injection, sufentanil citrate injection, oxeridine fumarate, injection, alfentanil hydrochloride injection, oxycodone hydrochloride injection, duloxetine hydrochloride enteric dissolving capsules, olan...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1978
• Employees: 5,923
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002262

Financial Performance

In 2024, SHE:002262's revenue was 5.70 billion, an increase of 13.01% compared to the previous year's 5.04 billion. Earnings were 1.14 billion, an increase of 10.28%.